Meiji Seika Pharma announced that it has committed to invest in the Global Health Security Fund (GHSF), a venture capital fund sponsored by Global Health Investment Corporation (GHIC). Through the investment, the company aims to support innovations addressing major global health challenges, including pandemic preparedness and antimicrobial resistance (AMR).
GHIC, a New York-based nonprofit organization, recently closed its second fund through GHSF. The organization uses private investment strategies designed to generate both global health impact and financial returns. Over more than a decade of investing in infectious disease innovation, GHIC has helped advance solutions to global health challenges, with portfolio companies commercializing more than a dozen products that have reached over 600 million people worldwide.
GHIC has also partnered with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and introduction of technologies and medical products that address health security threats. Through this public-private partnership, GHIC launched GHSF as a venture capital fund focused on strengthening public health preparedness and supporting innovations that can help detect, prevent, and respond to future public health emergencies.
Meiji Seika Pharma said the investment aligns with its long-standing focus on infectious disease innovation. The company has been active in the development of therapeutics and vaccines for infectious diseases since launching penicillin in 1946 and continues to invest in next-generation healthcare innovations and strategic partnerships.
The company believes that working with GHIC will help advance research and development efforts in infectious diseases while supporting solutions for future pandemics and the growing threat of antimicrobial resistance.
GHIC noted that the fund’s mission is to bring together investors and partners from across the public and private sectors to accelerate transformational technologies that improve global health security and strengthen health systems worldwide.
Through the collaboration, Meiji Seika Pharma intends to expand its contribution to addressing unmet medical needs in infectious diseases while helping support the development of innovative technologies that improve preparedness for future health crises.
KEY QUOTES:
“Investing in GHIC’s GHSF was a straightforward decision for us. GHIC’s mission to address unmet global health needs closely aligns with Meiji Seika Pharma’s long-standing commitment to infectious disease innovation. We are pleased to participate in GHSF as a limited partner and to collaborate with GHIC’s highly experienced team. Together, we aim to drive meaningful impact in areas such as infectious diseases, where unmet medical needs remain substantial but sustained pharmaceutical engagement has been limited due to challenging market dynamics.”
Toshiaki Nagasato, President and Representative Director, Meiji Seika Pharma
“Global health security requires sustained investment, continued innovation, and strong collaboration across the public and private sectors. By leveraging the commitment and contributions of our investors and partners, the Global Health Security Fund is accelerating transformational technologies to achieve our shared vision for a safer and healthier world.”
Labeeb Abboud, Chairman and CEO, Global Health Investment Corporation (GHIC)
